中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D System and Platforms
Innovation Strategy
Innovation Pipeline
Achievements
Products
Drug Products
Next-gen Therapies
APIs
Boranes
Services
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2026
2025
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2026
In 2025
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit Pharmaceuticals to Showcase at DCAT Week 2026, Invites Global Partners to New York
Dr. Keene Wei, President of Viwit, Invited to Speak at the 2026 In Vivo Cell Therapy Innovation Summit
Innovation Drives Development, Focus Makes a "Little Giant": Viwit Recognized as a National Specialized, Refined, Distinctive, and Innovative "Little Giant" Enterprise in the Seventh Batch!
Viwit Pharmaceuticals Co., Ltd. Embarks on a New Journey: Fully Focused on Innovation, Driving the Future with Insight and Science
Viwit Pharmaceuticals Granted "Radiation Safety License": A Dual Milestone in Compliance and Innovation
Advancing into a New Chapter: Viwit Pharma Officially Launches Frontier Exploration in Targeted Gene and Cell Therapies
Viwit 2016 Annual Gala Successfully Held
On January 24th, all employees of Viwit held the 2016 Spring Festival in the blue brick and red tile Longyuan Ancient Town. The company's president Wei Yanjun gave a congratulatory message to all employees, affirmed the work in 2015, thanked all the wise people for their hard work over the past year, expressed their expectations for future development, and sent the deepest to all employees and their families. blessing.
24
2016
/
01
Congratulations to Viwit Pharmaceutical Co.,Ltd for passing Cofepris certification of the Ministry of Health of Mexico
In October 2015, Viwit Pharmaceutic Co., Ltd. ushered in the GMP audit of the Atazanavir Sulfate API by the Mexican official Cofepris. After five days of intensive and orderly inspection and certification, we have all zero defects It successfully passed the on-site inspection and finally obtained the GMP certificate issued by the Mexican Ministry of Health Cofepris. The Cofepris certification of the Mexican Ministry of Health further strengthened the company's GMP concept and improved the production management system. At the same time, it opened the door to the Latin American market for the company's sales of APIs and became the cornerstone of future regulatory market certification.
2015
10
Search
中文
EN
